Koen Dewaele, MSc Biology, has more than 25 years experience in the diagnostic industry. He joined the Innogenetics marketing team in 1999 as a product manager. He has held several positions since then but could excel most when leading the Alzheimer program in 2004 – 2006 and in 2010. He has a good understanding of both the business and the science which helps to define the best strategy. Besides he is an organizer and people manager. Before joining Innogenetics, Koen has held M&S positions in several other IVD companies (Akzo, Baxter, Sigma Aldrich). In 2008, he organized – together with Flanders Bio- and presided a successfully attended seminar on companion diagnostics.
KDIV Consult bvba is represented by its permanent representative Koen Dewaele
Paul J. Appermont, Dr. Jur. MBA, started his career in 1972 as an international Business Lawyer at Janssen Pharma/J&J. He served as VP Trade & Licensing for Biogen S.A. (Geneva) from 1981 until 1985.He joined Innogenetics in 1987 as Executive Consultant responsible for Business Development focused on Alzheimer's disease and on business in the Far East, in particular in China. His first contacts with China date back to 1979 as a pioneer of the Janssen Pharma Joint Venture in Xi'an. He also served in the past as a consultant to a number of innovative companies, including Sorin Biomedica and as President of the Benelux Licensing Executives Society. He was President of the Belgian Bioindustries Association and Board member of EuropaBio. Dr. Appermont studied at the Universities of Leuven and Geneva and has 38 years of experience in the pharmaceutical and biotech industry. He's a dealmaker & networker, 'From Contact to Contract'. Paul is also the founder and President of ChinArt, specialised in 'objets d'art' and in consultancy work.
Chinart bvba is represented by its permanent representative Paul Appermont
Benedicte Laureys has been a director at the board of Van de Velde NV, a leading player in the women’s lingerie sector, since 2006. As co-owner of the family business, she is involved in building the company around Lingerie Styling and strong brand aspirations with the consumer at the center. She is also a board member of the retail group Rigby&Peller US and UK. Benedicte is working on a strategy that leads to an improved store experience and store positioning.
Together with her sister, Veronique Laureys, she runs the investment vehicle 'Ambo Holding Nv’. Ambo Holding invested in ADx NeuroSciences as they believe in the expertise of the management to contribute to diagnosis of dementia and the treatment of Alzheimer’s and other neurodegenerative diseases. Benedicte believes that the ability to think makes us human and therefore fully supports ADx NeuroSciences’ mission to make sure we don’t lose that capability during the aging process.
Patrick De Backer is Dr. in Veterinary Medicine with a Ph.D. in Veterinary Pharmacology and Toxicology, 1986 and had a degree in General management, 1987, School of Management, RUG. Patrick started as full-time Assistant at the Department of Veterinary Pharmacology and Toxicology, Faculty of Veterinary Medicine, Gent 1986-1996. He is founder & General Manager of Oropharma n.v., Research & Development of veterinary pharmaceuticals, Temse 1987-2005 and founder of Orotech N.V. (2005). He is teaching Pharmacology and Toxicology at the Faculty of Veterinary Medicine, Ghent University, Belgium, and Wuhan University, Republic of China. Patrick is diplomate of the European College of Veterinary Pharmacology and Toxicology, 2000 and has been invited speaker on International Congresses and chairperson of a) the European College of Veterinary Pharmacology and Therapeutics, 1983-2009 b)antimicrobial agents in Veterinary Medicine (AAVM), 2002/2004/2006/2008/2010 . He is author of more than 140 scientific publications.
Orlay cva is represented by its permanent representative Patrick De Backer
Ilse Sienaert has a MSc in Industrial Sciences Biochemistry and a MSc in Engineering in Cell and Gene Biotechnology. After obtaining her Ph.D. at KU Leuven and a post-doc at the U. of Texas Health Science Center, San Antonio Ilse joined 4AZA Biosciences in 2002, a spin-off company of KU Leuven focused on the development of new immunosuppressive drugs. Over the following 14 years she further built up business experience in a start-up and SME environment. In 2008 she started to work as an innovation advisor for SMEs for the Innovation center Vlaams-Brabant. In 2011 she joined the Spin-offs & Innovation unit of KU Leuven Research & Development (LRD) as an innovation manager, allowing her to fully focus on incubating, launching and developing life science and medical technology-oriented spin-offs. During the last 5 years she executed due diligences for the Gemma-Frisius Fund and LRD and closed several investment deals. Currently she occupies two board seat in KU Leuven spin-offs and follows-up several other boards as key contact for LRD and the Gemma-Frisius Fund. She has experience in business development, venture capital financing and deal making for technology start-ups.
Dirk Beecker started his career with a vocational training in a German bank and received a degree in economics at the University of Kiel, Germany and the University of Kansas, USA. He has 20 years of experience in auditing and consulting of international companies including stock-listed companies. Dirk is a certified German public tax advisor and public auditor. He started his auditing and consulting career with Arthur Andersen in 1996 in Hamburg and joined BDO Wirtschaftsprüfungsgesellschaft AG in Lübeck in 2002. From 2007 to 2015 he was a partner at BDO Wirtschaftsprüfungsgesellschaft AG and co-head of the BDO Lübeck office. Dirk particularly consulted companies in the technology and manufacturing sector and accompanied several IPOs. In 2015 he joined the finance/controlling department of EUROIMMUN Medizinische Labordiagnostika AG, Lübeck, a leading developer and manu¬facturer of medical laboratory reagents, especially for the diagnosis of allergies, autoimmune and infectious diseases. Dirk is responsible for the finances and controlling of the international subsidiaries and other equity investments of the EUROIMMUN Group.